Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sutro Biopharma, Inc. (STRO : NSDQ)
 
 • Company Description   
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.

Number of Employees: 224

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.74 Daily Weekly Monthly
20 Day Moving Average: 587,231 shares
Shares Outstanding: 46.93 (millions)
Market Capitalization: $222.47 (millions)
Beta: 1.11
52 Week High: $23.70
52 Week Low: $4.43
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -30.40% -23.73%
12 Week -44.04% -39.28%
Year To Date -68.14% -62.12%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
111 Oyster Point Blvd
-
South San Francisco,CA 94080
USA
ph: 650-881-6500
fax: -
ajchang@sutrobio.com http://www.sutrobio.com
 
 • General Corporate Information   
Officers
William J. Newell - President; Chief Executive Officer
Edward C. Albini - Chief Financial Officer and Corporate Secretary
Michael Dybbs - Director
John G. Freund - Director
Joseph M. Lobacki - Director

Peer Information
Sutro Biopharma, Inc. (CORR.)
Sutro Biopharma, Inc. (RSPI)
Sutro Biopharma, Inc. (CGXP)
Sutro Biopharma, Inc. (BGEN)
Sutro Biopharma, Inc. (GTBP)
Sutro Biopharma, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 869367102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 46.93
Most Recent Split Date: (:1)
Beta: 1.11
Market Capitalization: $222.47 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.70 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.11 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.01
Price/Cash Flow: -
Price / Sales: 4.19
EPS Growth
vs. Year Ago Period: -95.35%
vs. Previous Quarter: -1.20%
Sales Growth
vs. Year Ago Period: -59.77%
vs. Previous Quarter: -44.65%
ROE
03/31/22 - -42.97
12/31/21 - -32.96
09/30/21 - -37.80
ROA
03/31/22 - -33.22
12/31/21 - -26.51
09/30/21 - -31.34
Current Ratio
03/31/22 - 5.90
12/31/21 - 5.24
09/30/21 - 7.07
Quick Ratio
03/31/22 - 5.90
12/31/21 - 5.24
09/30/21 - 7.07
Operating Margin
03/31/22 - -215.16
12/31/21 - -153.28
09/30/21 - -195.40
Net Margin
03/31/22 - -215.16
12/31/21 - -170.55
09/30/21 - -213.36
Pre-Tax Margin
03/31/22 - -215.16
12/31/21 - -170.55
09/30/21 - -213.36
Book Value
03/31/22 - 4.70
12/31/21 - 5.46
09/30/21 - 6.15
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.06
12/31/21 - 0.06
09/30/21 - 0.07
Debt-to-Capital
03/31/22 - 5.47
12/31/21 - 5.87
09/30/21 - 6.19
 

Powered by Zacks Investment Research ©